Pub Date : 2024-09-26DOI: 10.4274/ejbh.galenos.2024.2024-4-3
Murat Kaya, Asmaa Abuaisha, İlknur Süer, Melike Sultan Alptekin, Fahrünnisa Abanoz, Selman Emiroğlu, Şükrü Palanduz, Kıvanç Cefle, Şükrü Öztürk
Objective: Breast cancer (BC) is highly heterogeneous and one of the most common cancers. Luminal A (LUM A) is a subtype of BC with a better prognosis than other BC subtypes. The molecular mechanisms underlying the initiation and progression of the LUM A subtype are still unclear. Big data generated from microarray and sequencing systems can be re-analyzed, especially with the help of various in silico tools developed in recent years, and made applicable for in vitro and in vivo research. This work aimed to identify genes that may play a role in the progression of LUM A subtype of BC using both computational and laboratory-based methods.
Materials and methods: Overlapping genes associated with BC were identified from the The Cancer Genome Atlas database, GSE233242, GSE100925 geodata sets, and the geneshot tool. The network functional analysis between overlapping genes was determined with STRING 12.0. Expression levels of overlapping genes in BC were investigated with the TNMplot (https://tnmplot.com/analysis/) in silico tool. The effect of overlapping genes on the overall survival of LUM A cancer patients was defined using the Kaplan-Meier plotter tool. Expressions of genes identified using bioinformatics data were investigated via quantitative real-time -polymerase chain reaction (qRT-PCR) in LUM A tumor and adjacent tissue samples. The data were evaluated using the t-test. Both the sensitivity and specificity of selected genes have been determined using the receiver operating characteristic curve.
Results: In silico investigation showed that eleven genes were possibly associated with BC. Among them CDC25A, AURKB, and TOP2A were considerably increased in LUM A samples according to qRT-PCR results. An overall survival analysis also showed that overexpression of these three genes could reduce the overall survival of LUM A patients.
Conclusion: The genes CDC25A, AURKB, and TOP2A may play crucial functions in LUM A pathogenesis. Therapeutic strategies that diminish the expression of these connected genes may enhance the prognosis of LUM A patients.
目的:乳腺癌(BC)具有高度异质性,是最常见的癌症之一。腔隙 A 型(LUM A)是乳腺癌的一种亚型,其预后优于其他亚型。LUM A亚型发病和进展的分子机制尚不清楚。微阵列和测序系统产生的大数据可以重新分析,特别是借助近年来开发的各种硅学工具,使其适用于体外和体内研究。这项工作旨在利用计算和实验室方法,找出可能在LUM A亚型BC进展过程中发挥作用的基因:从癌症基因组图谱数据库、GSE233242、GSE100925 地理数据集和 geneshot 工具中确定了与 BC 相关的重叠基因。重叠基因之间的网络功能分析由 STRING 12.0 确定。使用 TNMplot (https://tnmplot.com/analysis/) 硅工具研究了 BC 中重叠基因的表达水平。使用 Kaplan-Meier plotter 工具确定了重叠基因对 LUM A 癌症患者总生存期的影响。通过实时聚合酶链反应(qRT-PCR)对 LUM A 肿瘤和邻近组织样本中利用生物信息学数据确定的基因表达进行了研究。数据采用 t 检验进行评估。使用接收者操作特征曲线确定了所选基因的敏感性和特异性:硅学调查显示,有 11 个基因可能与乳腺癌有关。根据 qRT-PCR 结果,其中 CDC25A、AURKB 和 TOP2A 在 LUM A 样本中显著增加。总生存率分析也显示,这三个基因的过度表达会降低 LUM A 患者的总生存率:结论:CDC25A、AURKB和TOP2A基因可能在LUM A发病机制中发挥关键作用。结论:CDC25A、AURKB 和 TOP2A 基因可能在 LUM A 发病机制中发挥关键作用,减少这些相关基因表达的治疗策略可能会改善 LUM A 患者的预后。
{"title":"Overexpression of <i>CDC25A, AURKB</i>, and <i>TOP2A</i> Genes Could Be an Important Clue for Luminal A Breast Cancer.","authors":"Murat Kaya, Asmaa Abuaisha, İlknur Süer, Melike Sultan Alptekin, Fahrünnisa Abanoz, Selman Emiroğlu, Şükrü Palanduz, Kıvanç Cefle, Şükrü Öztürk","doi":"10.4274/ejbh.galenos.2024.2024-4-3","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2024.2024-4-3","url":null,"abstract":"<p><strong>Objective: </strong>Breast cancer (BC) is highly heterogeneous and one of the most common cancers. Luminal A (LUM A) is a subtype of BC with a better prognosis than other BC subtypes. The molecular mechanisms underlying the initiation and progression of the LUM A subtype are still unclear. Big data generated from microarray and sequencing systems can be re-analyzed, especially with the help of various <i>in silico</i> tools developed in recent years, and made applicable for <i>in vitro</i> and <i>in vivo</i> research. This work aimed to identify genes that may play a role in the progression of LUM A subtype of BC using both computational and laboratory-based methods.</p><p><strong>Materials and methods: </strong>Overlapping genes associated with BC were identified from the The Cancer Genome Atlas database, GSE233242, GSE100925 geodata sets, and the geneshot tool. The network functional analysis between overlapping genes was determined with STRING 12.0. Expression levels of overlapping genes in BC were investigated with the TNMplot (https://tnmplot.com/analysis/) <i>in silico</i> tool. The effect of overlapping genes on the overall survival of LUM A cancer patients was defined using the Kaplan-Meier plotter tool. Expressions of genes identified using bioinformatics data were investigated via quantitative real-time -polymerase chain reaction (qRT-PCR) in LUM A tumor and adjacent tissue samples. The data were evaluated using the t-test. Both the sensitivity and specificity of selected genes have been determined using the receiver operating characteristic curve.</p><p><strong>Results: </strong><i>In silico</i> investigation showed that eleven genes were possibly associated with BC. Among them <i>CDC25A, AURKB</i>, and <i>TOP2A</i> were considerably increased in LUM A samples according to qRT-PCR results. An overall survival analysis also showed that overexpression of these three genes could reduce the overall survival of LUM A patients.</p><p><strong>Conclusion: </strong>The genes <i>CDC25A, AURKB</i>, and <i>TOP2A</i> may play crucial functions in LUM A pathogenesis. Therapeutic strategies that diminish the expression of these connected genes may enhance the prognosis of LUM A patients.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"284-291"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-26DOI: 10.4274/ejbh.galenos.2024.2024-5-7
Leigh C Ward, Katrina Gaitatzis, Belinda Thompson, Vincent Singh Paramanandam, Louise A Koelmeyer
Objective: Breast cancer-related lymphedema (BCRL) is a common complication of breast cancer treatment that may result in swelling of the affected arm due to compromised lymphatic function. Implementing a screening program and early intervention for BCRL are important for effective management. Bioimpedance spectroscopy (BIS) is a commonly used tool for assessing BCRL. This study aimed to compare different normative ranges for BIS L-Dex scores in the detection of BCRL.
Materials and methods: Data from 158 women with clinically ascribed and indocyanine green confirmed BCRL were analysed. BIS measurements were obtained using an ImpediMed standing device, and L-Dex scores were calculated using published normative ranges for healthy individuals. Statistical analysis was performed to compare the concordance between different reference ranges in classifying individuals with lymphedema.
Results: The study found that L-Dex scores calculated using different normative ranges were highly correlated and essentially interchangeable in detecting BCRL. Approximately 90% of participants exceeded the L-Dex threshold for lymphedema, with minimal discrepancies between reference ranges. False negative rates were observed in some participants, likely due to early-stage BCRL with minimal lymph accumulation.
Conclusion: The findings suggest that BIS L-Dex scores are a valid indicator of BCRL, regardless of specific normative ranges used. Detection rates of clinically confirmed BCRL were consistent across different reference ranges, with minimal discrepancies. BIS remains a valuable tool for early detection and monitoring of BCRL. Future research should focus on longitudinal assessments and use of change in L-Dex scores for lymphedema monitoring and progression.
{"title":"Reliability of L-Dex Scores for Assessment of Unilateral Breast Cancer-Related Lymphedema.","authors":"Leigh C Ward, Katrina Gaitatzis, Belinda Thompson, Vincent Singh Paramanandam, Louise A Koelmeyer","doi":"10.4274/ejbh.galenos.2024.2024-5-7","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2024.2024-5-7","url":null,"abstract":"<p><strong>Objective: </strong>Breast cancer-related lymphedema (BCRL) is a common complication of breast cancer treatment that may result in swelling of the affected arm due to compromised lymphatic function. Implementing a screening program and early intervention for BCRL are important for effective management. Bioimpedance spectroscopy (BIS) is a commonly used tool for assessing BCRL. This study aimed to compare different normative ranges for BIS L-Dex scores in the detection of BCRL.</p><p><strong>Materials and methods: </strong>Data from 158 women with clinically ascribed and indocyanine green confirmed BCRL were analysed. BIS measurements were obtained using an ImpediMed standing device, and L-Dex scores were calculated using published normative ranges for healthy individuals. Statistical analysis was performed to compare the concordance between different reference ranges in classifying individuals with lymphedema.</p><p><strong>Results: </strong>The study found that L-Dex scores calculated using different normative ranges were highly correlated and essentially interchangeable in detecting BCRL. Approximately 90% of participants exceeded the L-Dex threshold for lymphedema, with minimal discrepancies between reference ranges. False negative rates were observed in some participants, likely due to early-stage BCRL with minimal lymph accumulation.</p><p><strong>Conclusion: </strong>The findings suggest that BIS L-Dex scores are a valid indicator of BCRL, regardless of specific normative ranges used. Detection rates of clinically confirmed BCRL were consistent across different reference ranges, with minimal discrepancies. BIS remains a valuable tool for early detection and monitoring of BCRL. Future research should focus on longitudinal assessments and use of change in L-Dex scores for lymphedema monitoring and progression.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"251-257"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Mastalgia or breast pain is a very common symptom in women attending breast clinic. The aim of this study was to evaluate whether imaging for mastalgia leads to cancer detection in an area where routine breast cancer screening services are underutilized.
Materials and methods: This prospective study was performed between 1st March 2021 to 31st January 2023 at a tertiary care academic institution of central India. All patients underwent through clinical examination by a surgeon. Then patients were referred for ultrasound and/or X-ray mammography (MMG) depending on age. Cancer detection rate was calculated.
Results: The final cohort consisted of 176 patients with mastalgia and without any abnormality on clinical breast examination. Sixteen patients had mass lesion on radiology and core needle biopsy resulted as infiltrating duct carcinoma in 7 patients and benign phylloides tumor in one patient. Overall case detection rate for cancer was 4%.
Conclusion: The breast cancer detection rate in patients presenting with mastalgia was low. However, in the absence of routine mammographic screening in the Indian general population, these would have been missed. Hence, diagnostic assessment for mastalgia is an appropriate strategy in countries where routine screening MMG is lacking.
目的:乳痛症或乳房疼痛是乳腺门诊就诊妇女的常见症状。本研究的目的是评估在常规乳腺癌筛查服务利用率较低的地区,乳房疼痛的影像学检查是否会导致癌症的发现:这项前瞻性研究于 2021 年 3 月 1 日至 2023 年 1 月 31 日在印度中部的一家三级医疗学术机构进行。所有患者均由外科医生进行临床检查。然后,根据患者的年龄转介其接受超声波和/或 X 射线乳腺放射摄影(MMG)检查。计算癌症检出率:最终结果:176 名患者患有乳腺增生,临床乳房检查未见异常。16名患者在放射学检查中发现肿块病变,7名患者的核心针活检结果为浸润性导管癌,1名患者为良性植物瘤。癌症总检出率为 4%:结论:乳腺增生患者的乳腺癌检出率较低。结论:乳腺增生患者的乳腺癌检出率较低,但在印度普通人群中缺乏常规乳房 X 线照相筛查的情况下,这些患者可能会被漏诊。因此,在缺乏常规MMG筛查的国家,对乳腺痛进行诊断评估是一项适当的策略。
{"title":"Mastalgia and Why It Should Be Evaluated With Imaging in Areas Where Use of Breast Cancer Screening Services are Unsatisfactory.","authors":"Shivangi Tomar, Akhilendra Singh Parihar, Sanjay Kumar Yadav, Rekha Agrawal","doi":"10.4274/ejbh.galenos.2024.2024-5-9","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2024.2024-5-9","url":null,"abstract":"<p><strong>Objective: </strong>Mastalgia or breast pain is a very common symptom in women attending breast clinic. The aim of this study was to evaluate whether imaging for mastalgia leads to cancer detection in an area where routine breast cancer screening services are underutilized.</p><p><strong>Materials and methods: </strong>This prospective study was performed between 1<sup>st</sup> March 2021 to 31<sup>st</sup> January 2023 at a tertiary care academic institution of central India. All patients underwent through clinical examination by a surgeon. Then patients were referred for ultrasound and/or X-ray mammography (MMG) depending on age. Cancer detection rate was calculated.</p><p><strong>Results: </strong>The final cohort consisted of 176 patients with mastalgia and without any abnormality on clinical breast examination. Sixteen patients had mass lesion on radiology and core needle biopsy resulted as infiltrating duct carcinoma in 7 patients and benign phylloides tumor in one patient. Overall case detection rate for cancer was 4%.</p><p><strong>Conclusion: </strong>The breast cancer detection rate in patients presenting with mastalgia was low. However, in the absence of routine mammographic screening in the Indian general population, these would have been missed. Hence, diagnostic assessment for mastalgia is an appropriate strategy in countries where routine screening MMG is lacking.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"258-261"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-26DOI: 10.4274/ejbh.galenos.2024.2024-5-2
Asel Wijesinghe, Kasun Lakmal, Jeewantha Senevirathna, Bhanu Wijetilake, J L T K Fernando, Umesh Jayarajah, Ajith De Silva, Kanchana Wijesinghe
Idiopathic granulomatous mastitis (IGM) is a debilitating, chronic, inflammatory condition of the breast. Several studies have emerged evaluating intralesional steroid (ILS) injection and topical steroid administration as a treatment for IGM. However, there is a dearth of international consensuses with regards to the management of IGM. Therefore, we have systematically reviewed the effectiveness of ILS in the management of IGM. A systematic search was conducted in PubMed and Cochrane Library databases, the Google Scholar website and by citation searching up to June 15th, 2023. Eight articles were selected and analyzed. A total of 397 IGM patients were included in the review. The mean patient age was 35.7 years, ranging from 23-62 years. The mean pre-treatment diameter of lesions was 27.5 mm. A total of 184 patients were treated with ILS. The mean complete clinical response time was 2.6 months. The overall complete response rate was 92.8%. Complications following ILS were minor, with hematoma, skin atrophy and hyperemia being commonly described, while avoiding the systemic side effects of oral steroid use, such as weight gain and hirsutism, which were the most commonly reported side effects with oral steroids. The recurrence rates in the ILS group (6.6%) appear to be lower than in the oral steroid group (25.8%) and surgery group (26.3%). ILS seem to show a favorable outcome in terms of complete response rate, complete clinical response time and has a lower recurrence rate and complication rate when compared to other intervention strategies. However, more comparative studies with standardized protocols are necessary to ascertain the optimum type, dosage and frequency of ILS regimens.
{"title":"The Use of Intralesional Corticosteroids in Idiopathic Granulomatous Mastitis: A Systematic Review.","authors":"Asel Wijesinghe, Kasun Lakmal, Jeewantha Senevirathna, Bhanu Wijetilake, J L T K Fernando, Umesh Jayarajah, Ajith De Silva, Kanchana Wijesinghe","doi":"10.4274/ejbh.galenos.2024.2024-5-2","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2024.2024-5-2","url":null,"abstract":"<p><p>Idiopathic granulomatous mastitis (IGM) is a debilitating, chronic, inflammatory condition of the breast. Several studies have emerged evaluating intralesional steroid (ILS) injection and topical steroid administration as a treatment for IGM. However, there is a dearth of international consensuses with regards to the management of IGM. Therefore, we have systematically reviewed the effectiveness of ILS in the management of IGM. A systematic search was conducted in PubMed and Cochrane Library databases, the Google Scholar website and by citation searching up to June 15th, 2023. Eight articles were selected and analyzed. A total of 397 IGM patients were included in the review. The mean patient age was 35.7 years, ranging from 23-62 years. The mean pre-treatment diameter of lesions was 27.5 mm. A total of 184 patients were treated with ILS. The mean complete clinical response time was 2.6 months. The overall complete response rate was 92.8%. Complications following ILS were minor, with hematoma, skin atrophy and hyperemia being commonly described, while avoiding the systemic side effects of oral steroid use, such as weight gain and hirsutism, which were the most commonly reported side effects with oral steroids. The recurrence rates in the ILS group (6.6%) appear to be lower than in the oral steroid group (25.8%) and surgery group (26.3%). ILS seem to show a favorable outcome in terms of complete response rate, complete clinical response time and has a lower recurrence rate and complication rate when compared to other intervention strategies. However, more comparative studies with standardized protocols are necessary to ascertain the optimum type, dosage and frequency of ILS regimens.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"233-240"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Mastalgia, a common complaint among women, denotes breast discomfort that can manifest as cyclical or non-cyclical. Reassurance, mechanical support and various non-pharmacological treatments, like flaxseeds, have been seen to have a good effect in treating mastalgia. Thus, the aim of this study was to investigates the efficacy of flaxseed in alleviating pain associated with mastalgia and its impact on the overall health-related quality of life among female patients.
Materials and methods: Conducted at a tertiary care center in Northern India over 18 months, it employed a single-arm interventional design. The participants included females aged 18 years and older presenting with breast pain at the Department of General Surgery. The intervention involved daily consumption of 30 g of milled flaxseed for each participant, administered over a period of six months. Pain severity was assessed using the visual analogue scale (VAS) before supplementation and at follow-up intervals up to six months. Concurrently, the Short Form-12 (SF-12) items Health Survey measured health-related quality of life, encompassing both physical and mental health domains. Statistical analysis employed parametric (paired t-test) and non-parametric tests (chi-square, McNemar) where appropriate, with statistical significance set at p<0.05.
Results: Two hundred women with mastalgia were included with a significant reduction in mean VAS scores from 6.03±0.83 at baseline to 2.19±0.66 at six months post-intervention (p = 0.0001). This reduction in pain intensity demonstrated a positive correlation with duration of flaxseed supplementation, notably declining after the initial three months. The mean difference in physical and mental SF-12 score at first visit and at 6 months after intervention was significant (p = 0.0001).
Conclusion: This study underscores the potential of flaxseed as a therapeutic option for managing mastalgia and enhancing health-related quality of life among affected individuals.
目的:乳房胀痛是女性的常见病,指乳房不适,可表现为周期性或非周期性。安抚、机械支持和各种非药物疗法(如亚麻籽)对治疗乳腺痛有良好效果。因此,本研究旨在调查亚麻籽对缓解乳腺增生相关疼痛的疗效及其对女性患者整体健康相关生活质量的影响:该研究在印度北部的一家三级医疗中心进行,历时 18 个月,采用单臂干预设计。参与者包括因乳房疼痛到普外科就诊的 18 岁及以上女性。干预措施包括每位受试者每天食用 30 克磨碎的亚麻籽,为期 6 个月。在补充亚麻籽之前和六个月的随访期间,使用视觉模拟量表(VAS)对疼痛的严重程度进行评估。同时,简表-12(SF-12)项目健康调查测量了与健康相关的生活质量,包括身体和心理健康领域。统计分析酌情采用参数检验(配对 t 检验)和非参数检验(秩和检验、McNemar 检验),统计显著性以 p 为限:200 名患有乳腺增生症的妇女接受了干预,其平均 VAS 分数从基线时的 6.03±0.83 显著降至干预后六个月时的 2.19±0.66(p = 0.0001)。疼痛强度的降低与补充亚麻籽的持续时间呈正相关,在最初的三个月后明显下降。首次就诊时和干预后 6 个月时,身体和精神 SF-12 评分的平均差异显著(p = 0.0001):这项研究强调了亚麻籽作为一种治疗选择的潜力,可用于控制乳腺增生并提高患者与健康相关的生活质量。
{"title":"Effect of Flaxseed on Pain Relief and Quality of Life in Patients With Mastalgia: A Single Arm Interventional Study.","authors":"Tabish Ansari, Priyanka Rai, Amarjot Singh, Rohit Srivastava, Sunil Singh, Vaibhav Raj Gopal","doi":"10.4274/ejbh.galenos.2024.2024-6-2","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2024.2024-6-2","url":null,"abstract":"<p><strong>Objective: </strong>Mastalgia, a common complaint among women, denotes breast discomfort that can manifest as cyclical or non-cyclical. Reassurance, mechanical support and various non-pharmacological treatments, like flaxseeds, have been seen to have a good effect in treating mastalgia. Thus, the aim of this study was to investigates the efficacy of flaxseed in alleviating pain associated with mastalgia and its impact on the overall health-related quality of life among female patients.</p><p><strong>Materials and methods: </strong>Conducted at a tertiary care center in Northern India over 18 months, it employed a single-arm interventional design. The participants included females aged 18 years and older presenting with breast pain at the Department of General Surgery. The intervention involved daily consumption of 30 g of milled flaxseed for each participant, administered over a period of six months. Pain severity was assessed using the visual analogue scale (VAS) before supplementation and at follow-up intervals up to six months. Concurrently, the Short Form-12 (SF-12) items Health Survey measured health-related quality of life, encompassing both physical and mental health domains. Statistical analysis employed parametric (paired t-test) and non-parametric tests (chi-square, McNemar) where appropriate, with statistical significance set at <i>p</i><0.05.</p><p><strong>Results: </strong>Two hundred women with mastalgia were included with a significant reduction in mean VAS scores from 6.03±0.83 at baseline to 2.19±0.66 at six months post-intervention (<i>p</i> = 0.0001). This reduction in pain intensity demonstrated a positive correlation with duration of flaxseed supplementation, notably declining after the initial three months. The mean difference in physical and mental SF-12 score at first visit and at 6 months after intervention was significant (<i>p</i> = 0.0001).</p><p><strong>Conclusion: </strong>This study underscores the potential of flaxseed as a therapeutic option for managing mastalgia and enhancing health-related quality of life among affected individuals.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"303-308"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-26DOI: 10.4274/ejbh.galenos.2024.2024-5-1
Almıla Coşkun Bilge, Zarife Melda Bulut
Objective: The aim of this retrospective study was to analyze the predictive capabilities of preoperative mammography, dynamic contrast-enhanced-magnetic resonance imaging (DCE-MRI), and diffusion-weighted imaging (DWI) in determining hormone receptor (HRc) status for pure ductal carcinoma in situ (DCIS) lesions.
Materials and methods: The study included a total of 79 patients who underwent preoperative mammography (MG) and MRI between December 2018 and December 2023 and were subsequently diagnosed with pure DCIS after surgery. The correlation between MG, DCE-MRI, and DWI features and estrogen receptor (ER) and progesterone receptor (PR) status was examined.
Results: Among the lesions, 44 were double HRc-positive (ER and PR-positive), 13 were single HRc-positive (ER-positive and PR-negative or ER-negative and PR-positive) and 22 were double HRc-negative (ER and PR-negative). The presence of symptom (p = 0.029), the presence of comedo necrosis (p = 0.005) and high histological grade (p<0.001) were found to be associated with ER and PR negativity. Amorphous microcalcifications were more commonly observed in the double HRc-negative group, while linear calcifications were more prevalent in both double and single HRc-positive groups (p = 0.020). Non-mass enhancement (NME) with a linear distribution was significantly more common in double HRc-negative lesions (38%), and NME with a segmental distribution in both double (43%) and single (50%) receptor-positive lesions (p = 0.042). Evaluation of DWI findings revealed that a higher lesion-to-normal breast parenchyma apparent diffusion coefficient (ADC) ratio statistically increased the probability of HRc positivity (p = 0.033).
Conclusion: Certain clinicopathological, mammography, and MRI features, along with the lesion-to-normal breast parenchyma ADC ratio, can serve as predictors for HRc status in DCIS lesions.
{"title":"The Predictive Role of Mammography, Dynamic Contrast-Enhanced Breast Magnetic Resonance Imaging and Diffusion-Weighted Imaging in Hormone Receptor Status of Pure Ductal Carcinoma <i>In Situ</i> Lesions.","authors":"Almıla Coşkun Bilge, Zarife Melda Bulut","doi":"10.4274/ejbh.galenos.2024.2024-5-1","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2024.2024-5-1","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this retrospective study was to analyze the predictive capabilities of preoperative mammography, dynamic contrast-enhanced-magnetic resonance imaging (DCE-MRI), and diffusion-weighted imaging (DWI) in determining hormone receptor (HRc) status for pure ductal carcinoma <i>in situ</i> (DCIS) lesions.</p><p><strong>Materials and methods: </strong>The study included a total of 79 patients who underwent preoperative mammography (MG) and MRI between December 2018 and December 2023 and were subsequently diagnosed with pure DCIS after surgery. The correlation between MG, DCE-MRI, and DWI features and estrogen receptor (ER) and progesterone receptor (PR) status was examined.</p><p><strong>Results: </strong>Among the lesions, 44 were double HRc-positive (ER and PR-positive), 13 were single HRc-positive (ER-positive and PR-negative or ER-negative and PR-positive) and 22 were double HRc-negative (ER and PR-negative). The presence of symptom (<i>p</i> = 0.029), the presence of comedo necrosis (<i>p</i> = 0.005) and high histological grade (<i>p</i><0.001) were found to be associated with ER and PR negativity. Amorphous microcalcifications were more commonly observed in the double HRc-negative group, while linear calcifications were more prevalent in both double and single HRc-positive groups (<i>p</i> = 0.020). Non-mass enhancement (NME) with a linear distribution was significantly more common in double HRc-negative lesions (38%), and NME with a segmental distribution in both double (43%) and single (50%) receptor-positive lesions (<i>p</i> = 0.042). Evaluation of DWI findings revealed that a higher lesion-to-normal breast parenchyma apparent diffusion coefficient (ADC) ratio statistically increased the probability of HRc positivity (<i>p</i> = 0.033).</p><p><strong>Conclusion: </strong>Certain clinicopathological, mammography, and MRI features, along with the lesion-to-normal breast parenchyma ADC ratio, can serve as predictors for HRc status in DCIS lesions.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"241-250"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-26DOI: 10.4274/ejbh.galenos.2024.2024-5-11
Ali Hasan Abdulla, Reem Althawadi, Ahmed Zuhair Salman, Tareq Hamed Altaei, Amina Mohamed Mahdi, Hussain Adnan Abdulla
Objective: The Sentinel Node vs. Observation After Axillary Ultra-Sound (SOUND) trial reported that omission of axillary surgery was not inferior to sentinel lymph node biopsy (SLNB) in those with cT1 breast cancer and negative preoperative axillary ultrasound. The aim of our study was to evaluate the clinical characteristics of early breast cancer patients undergoing breast conserving surgery (BCS) at our institution in order to investigate the exportability of SOUND criteria to our patient population.
Materials and methods: We retrospectively reviewed patients with cT1N0 breast cancer undergoing BCS and adjuvant radiotherapy according to the SOUND trial criteria. Comparison was made between the eligible group of our cohort and the SLNB arm of the SOUND trial.
Results: The proportion of younger patients was higher in our eligible cohort (37.7% vs. 17.5%, p = 0.002). Postmenopausal patients were more prevalent in the SOUND trial (79.4% vs. 56.6%, p = 0.004). On final pathology, tumours were more likely to be upgraded to T2 in our group (26.4% vs. 4.4%, p = 0.001). Patients in our cohort were more likely to receive adjuvant chemotherapy (37.7% vs. 20.1%, p = 0.002).
Conclusion: The clinicopathological differences between our cohort and the SOUND trial population could be attributed to aggressive tumours in Bahrain compared to Western countries. Our study may influence others to investigate the applicability of the SOUND trial in clinical practice. Nevertheless, it is a study that should generate multidisciplinary discussion in the de-escalation of axillary surgery.
{"title":"Applying the SOUND Trial for Omitting Axillary Surgery in Patients With Early Breast Cancer in Bahrain.","authors":"Ali Hasan Abdulla, Reem Althawadi, Ahmed Zuhair Salman, Tareq Hamed Altaei, Amina Mohamed Mahdi, Hussain Adnan Abdulla","doi":"10.4274/ejbh.galenos.2024.2024-5-11","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2024.2024-5-11","url":null,"abstract":"<p><strong>Objective: </strong>The Sentinel Node vs. Observation After Axillary Ultra-Sound (SOUND) trial reported that omission of axillary surgery was not inferior to sentinel lymph node biopsy (SLNB) in those with cT1 breast cancer and negative preoperative axillary ultrasound. The aim of our study was to evaluate the clinical characteristics of early breast cancer patients undergoing breast conserving surgery (BCS) at our institution in order to investigate the exportability of SOUND criteria to our patient population.</p><p><strong>Materials and methods: </strong>We retrospectively reviewed patients with cT1N0 breast cancer undergoing BCS and adjuvant radiotherapy according to the SOUND trial criteria. Comparison was made between the eligible group of our cohort and the SLNB arm of the SOUND trial.</p><p><strong>Results: </strong>The proportion of younger patients was higher in our eligible cohort (37.7% vs. 17.5%, <i>p</i> = 0.002). Postmenopausal patients were more prevalent in the SOUND trial (79.4% vs. 56.6%, <i>p</i> = 0.004). On final pathology, tumours were more likely to be upgraded to T2 in our group (26.4% vs. 4.4%, <i>p</i> = 0.001). Patients in our cohort were more likely to receive adjuvant chemotherapy (37.7% vs. 20.1%, <i>p</i> = 0.002).</p><p><strong>Conclusion: </strong>The clinicopathological differences between our cohort and the SOUND trial population could be attributed to aggressive tumours in Bahrain compared to Western countries. Our study may influence others to investigate the applicability of the SOUND trial in clinical practice. Nevertheless, it is a study that should generate multidisciplinary discussion in the de-escalation of axillary surgery.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"270-276"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-26DOI: 10.4274/ejbh.galenos.2024.2024-6-3
Corrado Tinterri, Shadya Sara Darwish, Erika Barbieri, Andrea Sagona, Valeriano Vinci, Damiano Gentile
Objective: The aim of this study was to evaluate the clinical outcomes of breast cancer (BC) patients treated with neoadjuvant chemotherapy (NAC) followed by mastectomy, focusing on cases achieving pathologic complete response (pCR). The implications of residual ductal carcinoma in situ (DCIS) on prognosis and survival were examined.
Materials and methods: A retrospective cohort study included BC patients treated with NAC followed by mastectomy at the breast unit of IRCCS Humanitas Research Hospital between March 2010 and October 2021. Patients were sub-grouped into two: Those with residual DCIS (ypTis) and those with complete response without residual tumor (ypT0). Key variables such as demographics, tumor characteristics, treatment regimens, and survival outcomes were analyzed.
Results: Of 681 patients treated with NAC, 175 achieved pCR, with 60 undergoing mastectomy. Among these 60 patients, 24 had residual DCIS (ypTis) while 36 had no residual invasive or in situ disease (ypT0). Patients with ypTis had higher rates of multifocal disease (62.5% vs. 27.8%, p = 0.006) and stage III disease (37.5% vs. 11.1%, p = 0.046). Triple-negative breast cancer was more prevalent in the ypT0 group (55.6% vs. 20.8%, p = 0.005). During a mean follow-up of 47 months, 11 patients experienced recurrence, with no significant differences in disease-free survival (DFS) and overall survival (OS) between the groups (p = 0.781, p = 0.963, respectively).
Conclusion: Residual DCIS after NAC did not significantly impact DFS or OS compared to complete pathologic response without residual DCIS. This study underscores the need for further research to refine pCR definitions and improve NAC's prognostic and therapeutic roles in BC management.
{"title":"Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer Patients Treated With Mastectomy: Indications for Treatment and Oncological Outcomes.","authors":"Corrado Tinterri, Shadya Sara Darwish, Erika Barbieri, Andrea Sagona, Valeriano Vinci, Damiano Gentile","doi":"10.4274/ejbh.galenos.2024.2024-6-3","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2024.2024-6-3","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to evaluate the clinical outcomes of breast cancer (BC) patients treated with neoadjuvant chemotherapy (NAC) followed by mastectomy, focusing on cases achieving pathologic complete response (pCR). The implications of residual ductal carcinoma <i>in situ</i> (DCIS) on prognosis and survival were examined.</p><p><strong>Materials and methods: </strong>A retrospective cohort study included BC patients treated with NAC followed by mastectomy at the breast unit of IRCCS Humanitas Research Hospital between March 2010 and October 2021. Patients were sub-grouped into two: Those with residual DCIS (ypTis) and those with complete response without residual tumor (ypT0). Key variables such as demographics, tumor characteristics, treatment regimens, and survival outcomes were analyzed.</p><p><strong>Results: </strong>Of 681 patients treated with NAC, 175 achieved pCR, with 60 undergoing mastectomy. Among these 60 patients, 24 had residual DCIS (ypTis) while 36 had no residual invasive or <i>in situ</i> disease (ypT0). Patients with ypTis had higher rates of multifocal disease (62.5% <i>vs</i>. 27.8%, <i>p</i> = 0.006) and stage III disease (37.5% <i>vs</i>. 11.1%, <i>p</i> = 0.046). Triple-negative breast cancer was more prevalent in the ypT0 group (55.6% <i>vs</i>. 20.8%, <i>p</i> = 0.005). During a mean follow-up of 47 months, 11 patients experienced recurrence, with no significant differences in disease-free survival (DFS) and overall survival (OS) between the groups (<i>p</i> = 0.781, <i>p</i> = 0.963, respectively).</p><p><strong>Conclusion: </strong>Residual DCIS after NAC did not significantly impact DFS or OS compared to complete pathologic response without residual DCIS. This study underscores the need for further research to refine pCR definitions and improve NAC's prognostic and therapeutic roles in BC management.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"277-283"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-26DOI: 10.4274/ejbh.galenos.2024.2024-4-5
Cedric Pluguez-Turull, Cinthia Del Toro, Nicole Brofman, Yara Z Feliciano
We present the case of a forty-year-old asymptomatic female with no personal or family history of breast cancer, who underwent a core needle biopsy (CNB) following the identification of a focal asymmetry in the right breast on screening mammography. Eight months later, a prominent adjacent vascular structure with a round outpouching was detected on breast ultrasound, confirmed as a post-biopsy pseudoaneurysm. Breast pseudoaneurysms, although exceedingly rare, result from inadvertent vessel puncture during core needle biopsies, particularly when larger gauge needles are used. They present as palpable, throbbing lumps in the breast and are well-defined heterogeneous structures that exhibit turbulent flow with a feeding artery on color Doppler imaging. This swirling sign showing a to-and-fro waveform is also known as the "yin-yang" sign on Doppler ultrasound. Post-CNB pseudoaneurysms in the breast, while rare, should be considered as potential complications following core need biopsy. Understanding their characteristic imaging features, risk factors, and available management options is essential for early diagnosis and appropriate treatment. This case underscores the importance of vigilance in biopsy procedures and the need for prompt recognition and intervention in case of such complications.
本病例是一名四十岁的无症状女性,无个人或家族乳腺癌病史,在乳房 X 光筛查中发现右侧乳房有局灶性不对称,随后接受了核心针活检(CNB)。八个月后,她在乳腺超声波检查中发现了一个突出的邻近血管结构,并伴有圆形外囊,证实为活检后假性动脉瘤。乳腺假性动脉瘤虽然极为罕见,但却是在核心针活检过程中不慎刺穿血管造成的,尤其是在使用较大规格的针头时。乳房假性动脉瘤表现为乳房内可触及的搏动性肿块,是界限清晰的异质结构,在彩色多普勒成像中表现为进血动脉的湍流。在多普勒超声检查中,这种显示往返波形的漩涡征也被称为 "阴阳 "征。乳腺核芯穿刺活检后假性动脉瘤虽然罕见,但应被视为核芯穿刺活检后的潜在并发症。了解假性动脉瘤的影像学特征、风险因素和可用的治疗方案对于早期诊断和适当治疗至关重要。本病例强调了在活检过程中保持警惕的重要性,以及在出现此类并发症时及时识别和干预的必要性。
{"title":"Pseudoaneurysm in the Axillary Tail of the Breast After A Core Needle Biopsy.","authors":"Cedric Pluguez-Turull, Cinthia Del Toro, Nicole Brofman, Yara Z Feliciano","doi":"10.4274/ejbh.galenos.2024.2024-4-5","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2024.2024-4-5","url":null,"abstract":"<p><p>We present the case of a forty-year-old asymptomatic female with no personal or family history of breast cancer, who underwent a core needle biopsy (CNB) following the identification of a focal asymmetry in the right breast on screening mammography. Eight months later, a prominent adjacent vascular structure with a round outpouching was detected on breast ultrasound, confirmed as a post-biopsy pseudoaneurysm. Breast pseudoaneurysms, although exceedingly rare, result from inadvertent vessel puncture during core needle biopsies, particularly when larger gauge needles are used. They present as palpable, throbbing lumps in the breast and are well-defined heterogeneous structures that exhibit turbulent flow with a feeding artery on color Doppler imaging. This swirling sign showing a to-and-fro waveform is also known as the \"yin-yang\" sign on Doppler ultrasound. Post-CNB pseudoaneurysms in the breast, while rare, should be considered as potential complications following core need biopsy. Understanding their characteristic imaging features, risk factors, and available management options is essential for early diagnosis and appropriate treatment. This case underscores the importance of vigilance in biopsy procedures and the need for prompt recognition and intervention in case of such complications.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"313-315"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-26DOI: 10.4274/ejbh.galenos.2024.2024-5-10
Gökhan Giray Akgül, Sümeyra Güler, Simay Akyüz, Duygu Bayram, İbrahim Burak Bahçecioğlu, Müjdat Turan, Hikmet Erhan Güven, Mehmet Ali Gülçelik, Kerim Bora Yılmaz
Necrotizing fasciitis is a rare but potentially lethal infection of the skin and soft tissue, commonly seen in the perianal and gluteal regions. Concomitant diabetes is a predisposing factor. Primary necrotizing fasciitis of the breast is rare in healthy women. In this article, we present a very rare case of breast necrotizing fasciitis in the context of the literature. We report the case of a 35-year-old female patient who had given birth two months prior to admission and developed necrotizing fasciitis of the breast during lactation. The patient presented to the emergency department with sepsis. Examination revealed widespread erythema, dark discoloration, edema, and necrotic areas indicative of wet gangrene and crepitation in the left breast. Necrotizing fasciitis is a rapid and aggressive disease that can be fatal, and delayed diagnosis may unfortunately result in death. Therefore, careful evaluation of all suspected cases, especially for patients with risk factors, is crucial for early diagnosis and timely treatment. This case highlights the importance of recognizing necrotizing fasciitis of the breast in lactating women to ensure prompt and appropriate management, potentially saving lives.
{"title":"Rare Breast Emergency: A Case of Necrotizing Fasciitis of the Breast in a Lactating Patient.","authors":"Gökhan Giray Akgül, Sümeyra Güler, Simay Akyüz, Duygu Bayram, İbrahim Burak Bahçecioğlu, Müjdat Turan, Hikmet Erhan Güven, Mehmet Ali Gülçelik, Kerim Bora Yılmaz","doi":"10.4274/ejbh.galenos.2024.2024-5-10","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2024.2024-5-10","url":null,"abstract":"<p><p>Necrotizing fasciitis is a rare but potentially lethal infection of the skin and soft tissue, commonly seen in the perianal and gluteal regions. Concomitant diabetes is a predisposing factor. Primary necrotizing fasciitis of the breast is rare in healthy women. In this article, we present a very rare case of breast necrotizing fasciitis in the context of the literature. We report the case of a 35-year-old female patient who had given birth two months prior to admission and developed necrotizing fasciitis of the breast during lactation. The patient presented to the emergency department with sepsis. Examination revealed widespread erythema, dark discoloration, edema, and necrotic areas indicative of wet gangrene and crepitation in the left breast. Necrotizing fasciitis is a rapid and aggressive disease that can be fatal, and delayed diagnosis may unfortunately result in death. Therefore, careful evaluation of all suspected cases, especially for patients with risk factors, is crucial for early diagnosis and timely treatment. This case highlights the importance of recognizing necrotizing fasciitis of the breast in lactating women to ensure prompt and appropriate management, potentially saving lives.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"309-312"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}